Pay in 4 interest-free payments of $7.38 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Binary Classification for Analysis Overview Although these 3 components can each vary in intensity (eg, how many coaching sessions, how frequently weight was logged, app login outside weight logging), for the primary analysis we simplified the categorization into engaged or nonengaged, as determined in consultation with the clinical team: Engaged Met any one (or more) of the following three criteria at least once during the study period: (1) attended 1 weight coaching session (group or individual), (2) tracked weight 1 per week in the app, or (3) logged into the app (for features other than only weight logging) at least once for the duration of the program
Tirzepatide (Mounjaro and Zepbound) - Tirzepatide is a dual-action therapy that targets GLP-1 and GIP (glucose-dependent insulinotropic peptide) receptors for enhanced weight loss benefits
patients should confirm current details on the official MEDVi website
More importantly, the decision reflects something bigger than a single drug
For the 15% threshold, while differences were less pronounced, 86.5% of engaged participants had not reached this target by month 5, compared with 93.5% of nonengaged participants ( P =.02)
US$ 24.49
US$ 25.67
US$ 28.02
US$ 20.07
US$ 22.38
US$ 25.37
